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Résumé en
anglais
Oxazaphosphorines (Oxaza) represented by cyclophosphamide (CPA) and ifosfamide
(IFO) are still the corner stone of several polychemotherapy protocols as they are
widely indicated in the treatment of numerous cancer from soft tissue sarcomas to
lymphomas and immune-related diseases. However, Oxaza are prodrugs requiring
cytochrome (CYP) P450 bioactivation responsible of limiting adverse effects. In the
case of IFO, bioactivation leads to a low release of 4-OH-IFO (10%), which generates
the active nitrogen mustard displaying DNA cross-links. Associated toxicities of IFO
due to acrolein, (urotoxicity) and to chloroacetaldehyde (neuro and nephrotoxicity)
have been described. Thus, increasing IFO therapeutic index could be of major
interest. To circumvent these toxicities, our team has designed new pre-activated IFO
analogs to avoid CYP bioactivation (Skarbek et al J Med Chem 2015). Among these
analogues some have the ability to self-assemble as nanoassemblies (NAs), the others
can be encapsulated within nano-lipid capsules (NLCs). These new drug delivery
systems (DDS) can take advantage of passive targeting, as stealthiness of these DDS
can be provided by PEGylation by using Cholesterol-polyethylene glycol or the use of
surfactant. These DDS can also be functionalized by appropriate monoclonal
antibodies leading to multi stage DDS with active targeting properties. Regarding
CPA, it has been shown and described in literature that low doses of CPA enhance the
immunity by promoting differentiation of CD4⁺ cell toward Th1. As IFO is isomeric
form of CPA, it was assumed that IFO could also have such properties. Studies on
immunocompetent MCA205 mouse model, an immunogenic fibrosarcoma mouse
model, demonstrate a dose-dependent immunomodulation of IFO towards a
modulation of the secretion of IFNy, IL-17A and IL-6 cytokines. The ongoing
experiments on mouse model depleted in CD4⁺ T cells and CD8⁺ T cells show the
antitumor efficacy of IFO 150mg/kg on these immune cells in tumor regression. Both
strategies could lead to the design of nano-immuno-conjugates (NICs) which could
benefit of the immunomodulatory effects of X-Oxaza combined to their
antiproliferative properties targeted through immune checkpoint antibodies. These
new functionalized DDS may provide a useful strategy to give specificity to active
drugs used for many years in clinical practice. Both DDS could be grafted with mAbs
which could lead to a new family of DDS aiming to combine antiproliferative and
immunomodulatory properties for a dual antitumoral action Citation Format: Julia
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